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Abstract:  Apoptosis is a cell death programme primordial to cellular homeostasis 
efficiency. This normal cell suicide program is the result of the activation of a cascade of 
events in response to death stimuli. Apoptosis occurs in normal cells to maintain a balance 
between cell proliferation and cell death. A deregulation of this balance due to 
modifications in the apoptosic pathway leads to different human diseases including 
cancers. Apoptosis resistance is one of the most important hallmarks of cancer and some 
new therapeutical strategies focus on inducing cell death in cancer cells. Nevertheless, 
cancer cells are resistant to treatment inducing cell death because of different mechanisms, 
such as DNA mutations in gene coding for pro-apoptotic proteins, increased expression of 
anti-apoptotic proteins and/or pro-survival signals, or pro-apoptic gene silencing mediated 
by DNA hypermethylation. In this context, aberrant DNA methylation patterns, 
hypermethylation and hypomethylation of gene coding for proteins implicated in apoptotic 
pathways are possible causes of cancer cell resistance. This review highlights the role of 
DNA methylation of apoptosis-related genes in cancer cell resistance. 
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1. Introduction  
Apoptosis or programmed cell death is a key suicide program dominant in the maintenance of 
cellular homeostasis and is initiated by the activation of a cascade of events preexisting within each 
cell, in response to death stimuli. Apoptosis contributes to a balance between cell proliferation and cell 
death in normal cells and disturbances in this pathway are often observed in human diseases. Among 
the hallmarks characterizing tumor escape (tumor reccurence despite resection and treatments) [2], 
apoptosis resistance is one of the most striking. Furthermore, even if new therapeutical strategies have 
emerged over the last decades to force cancer cells to undergo cell death, apoptosis resistance to 
treatment is still a major problem in cancer research and requires extensive research to improve our 
knowledge of apoptosis signaling. Cancers cells have developed numerous strategies of resistance to 
cell death such as DNA mutations in genes coding for pro-apoptotic proteins, increase expression of 
anti-apoptotic proteins and/or pro-survival signals, or discovered more recently, pro-apoptic gene 
silencing mediated by DNA hypermethylation. DNA methylation occur in about 50% CpG in the 
genome and results from a transfer of a CH3 (methyl group) from S-adenosyl methionine to the fifth 
carbon of cytosine in CpG motifs. CpG-rich areas referred as CpG islands (CGI) are more frequently 
methylated than isolated CpG and is generally associated with gene repression. Two distinct 
mechanisms of DNA methylation have been reported. The first is maintaining DNA methylation, 
which occurs on neosynthesized strands of DNA following replication and is mainly catalyzed by 
DNA methyltransferase 1 (Dnmt1) [3]. The second process is de novo (dn) methylation, which occurs 
on both strands of unmethylated DNA and is predominantly catalyzed by Dnmt3a and Dnmt3b [4]. 
Epigenetics appears highly implicated in gene dysregulation in cancers. Many cancers are 
characterized by global DNA hypomethylation [5,6], previously associated with chromosomal 
instability, and paradoxically with both local hypo and hypermethylations [7–9]. It is now well known 
that local hypomethylation may lead to abnormal activation of genes including oncogenes while 
hypermethylation could silence tumor suppressor genes (TSG) [10,11]. Similar phenomenon occur in 
genes regulating the apoptosis pathway and these epigenetic modifications could influence the balance 
between pro- and anti-apoptotic protein expression conferring a phenotype of apoptosis resistance in 
cancer cells. Indeed, hypermethylation of a number of genes implicated in the apoptosic pathway has been 
reported in cancer cells (Table 1). Among them, some seem more specific to a tumor type while others 
appear commonly methylated in cancers as illustrated by the methylation of Puma in lymphoma [12] while 
DAPK or RASSF1A methylations have been found in most cancers analyzed (Table 1). Moreover, 
hypermethylation of these genes could occur sporadically in tumors or cover a large sequence of the 
promoter and are found from low to high frequencies in cancer patients (Table 1). Owing to pleiotropic 
effects of p53 silencing in cancers, methylation of this gene has not been considered in this review (For 
a review, cf [13]). Cells 2013, 2  547 
 
 
Table 1. Apoptosis related genes are frequently methylated in tumors. Percentage of 
methylated tumors is indicated in brackets for significant histochemical studies. 
Gene 
methylated 
Cancer Ref 
APAF-1 
Melanoma, Leukemia, Testicular (100 vs. 60), Bladder (11), RCC 
(100) 
[14], [15], [16], [17], [18] 
Bad Myeloma  [19] 
Bak Myeloma  [19] 
Bax GBM,  Myeloma  [20],  [19] 
Bcl2L10  Gastric (38), Leukemia (12-45)  [21], [22] 
Bim CML  [23] 
Bik  Glioma (30), HCC, RCC, Prostate, Myeloma  [24], [25], [26], [27] 
BNIP3 
Pancreatic, Gastric (39), Breast, Colorectal, Leukemia, Myeloma, 
HCC 
[28], [29], [30], [31] 
Casp-8 
Medulloblastoma (62–81), Pituitary tract (54), Rhabdosarcoma (83 vs 
0), Phaeochromocytoma (31), Neuroblastoma (35-52 vs 0), 
Retinoblastoma (59 vs. 0), HCC (34), GBM (30), Bladder (19), Lung 
(0–45 vs. 0), Rectal, Breast, Prostate, Gastric 
[32], [33], [34], [35], [36], [37], 
[38], [39], [40], [41] 
DAPK 
Mesothelioma (20), Testicular (20–50 vs. 6), Nasopharyngial (76 vs. 
0), Pituitary (43), Colorectal (81), ACC (27), Lung (25–44), Biliary 
tract (21), Lymphoma (71–85), GBM (14), Gastric (22–70), 
Leukemia (36), Breast (13–88), CXCA (56–79), Cholangiocarcinoma 
(31), Bladder (74–77), RCC (33–55), Head and Neck (11–33), 
Myeloma (40), Oesophageal (50–60 vs. 20), Ovarian 
[42], [43], [44], [45], [46], [47], 
[48], [49], [16], [50], [36], [51], 
[52], [53] 
DcR1-2 
Glioma (60), Neuroblatoma (11–25), Prostate (50), Breast, Prostate 
(37–45), Ovarian (31–43), Breast (70), Lung (31), Mesothelioma 
(63), Bladder (42), CXCA (100), Lymphoma (41), Leukemia (26), 
Myeloma (56), Phaeochromocytoma (23–26) 
[54], [32], [55], [56], [57], [58], 
[37] 
DR4 or 5 
Breast, Melanoma, Ovarian (10–28), Phaeochromocytoma (41), 
Neuroblastoma 
[54], [59], [60], [37], [61] 
Fas  Lymphomas, CXCA, Colon, Prostatic (12), Lung  [62], [63], [64], [65] 
Hrk 
Colorectal (36), Gastric (32), GBM (27–43), PCNSL (31), Prostate 
(38) 
[66], [67], [68], [69] 
Puma Lymphoma  [12] 
RASSF1a 
ACC (42–45), Biliary tract (27), CRCC (45), Nasopharyngeal (71–84 
vs. 0), Ovarian (26), Gastric, Bladder (48–60 vs. 42), Thyroid, 
Neuoblastoma (83–93), Osteosarcoma (14 vs. 1), Lung (43 vs. 5), 
Breast (63–74), , HCC Hepatoblastoma (39–44), CXCA (26 vs. 0), 
Mesothelioma, Glioma (12–82), Endometrial, Liver (38), Prostate, 
Parathiroid (98), Lung (26), Testis (78 vs. 0), Melanoma (69), 
Colorectal (31), Retinoblastoma (98) 
[70], [71], [72], [73], [74], [75], 
[76], [32], [77], [78], [79], [80], 
[81], [82], [56], [83] 
SARP2 Pancreatic  (90–90  vs. 0–5), Colorectal, Oesophageal  [84] Cells 2013, 2  548 
 
 
Table 1. Cont. 
Gene 
methylated 
Cancer Ref 
TMS1 
Cholangiocarcinoma (36), Prostatic (47–65), Colorectal (25–41 vs. 
8), Ovarian (19 vs. 0), Thyroid (33), Breast (24–46), Gastric (32), 
GBM (21–57), Lung (41–70), Melanoma, Colorectal, Neuoblastoma, 
HCC, Pancreatic 
[85], [86], [87], [88], [89], [55], 
[90], [91], [92], [93], [94] 
TNFR10c 
Pancreatic (54–97), Choroid plexus (50), Neuroblastoma (21), Breast 
(48), Lung (37), Mesothelioma (43), Ependymomas (50) 
[95] 
XAF-1 
Colorectal (40), Gastric, Bladder, RCC, Prostatic (35 vs. 0), Lung, 
GBM (22), Oesophageal 
[96], [97], [98], [99], [34], [100]
2. Apoptotic Pathways  
Both the intrinsic and extrinsic pathway of apoptosis have been reported in mammals (Figure 1). 
Briefly, the intrinsic pathway involves a diverse array of non-receptor-mediated stimuli that produce 
intracellular signals that act directly on targets within the cell and are mitochondrial-initiated events 
which can be activated by the TSG p53 in response to cell injury such as DNA damage following 
radiation exposure. The Bcl2 protein family is composed of pro-apoptotic and anti-apoptotic members 
and are classified in three subfamilies with regards to their Bcl2 homology domains (BH). Bax and Bak 
present 3 BH domains (BH1-3) and are associated with pro-apoptotic properties. Conversely, anti-apoptotic 
proteins Bcl2, BclXL, Mcl-1, A1 and Bcl-W present 4 BH domains (BH1-4), and are capable of 
antagonizing Bax and Bak. Bim, Bik, Bad, Hrk, Noxa and Puma, which belong to the third subfamily 
(referred to BH3-only) and are devoided of BH1, 2 and 4. BH3-only proteins are also able to bind pro-
apoptotic proteins (like Bax and Bak) and activate or block their activity. Following the initiation of 
apoptosis, Bax and Bak undergo a conformational change, which consequently induces a 
permeabilization of the outer mitochondrial membrane releasing several mitochondrial proteins from 
intermembrane space (cytochrome c, Smac/diablo, HtrA2/omi). Interaction of APAF-1 with 
cytochrome c and proCasp 9 leads to the formation of the Apoptosome complex and the activation of 
Casp 9. Finally, cleavage of effector proCasp3 and pro-Casp7 into active Casp3 and 7 and nuclear 
fragmentation causes the formation of apoptotic bodies. The extrinsic pathway is activated in response 
to cytokines. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2 ligand) is able 
to selectively induce apoptosis in tumor cells with no significant untoward effect on normal cells. 
Apoptosis induced by TRAIL is initiated by its binding to death receptors (TRAIL-R1 or DR4 and 
TRAIL-R2 or DR5) followed by formation of the death-inducing signalling complex (DISC) upon 
recruitment of specific cytoplasmic proteins, Fas-associated death domain (FADD) and caspase-8 or  
-10. Binding of FasL to the extracellular area of Fas (APO1/CD95) induces a conformational change in 
the receptor and a recruitment of FADD (Fas-interacting DD) and proCasp 8 and proCas 10 effectors 
in the cytoplasmic region of the receptor via its death domain. Formation of this complex induces an 
increased concentration of initiator caspases: proCasp 8 and 10 on Fas receptor and their automatic 
cleavage to active Casp 8 and 10. Once activated, these caspases can directly activate Casp 3 or 
connect to the intrinsic pathway by the cleavage of BID into tBID catalysed by Casp 8, which 
consequently leads to the activation of Bax and mitochondrial pathway and further Casp 3 activation. Cells 2013, 2  549 
 
 
Figure 1. Mechanism of apoptosis. Activation of initiators caspase 8 and 10 are mediated 
in response to extrinsic stimuli and apoptosis signaling is controlled by anti- and pro-apoptotic 
protein interactions. 
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3. DNA Hypo/Hypermethylations in Apoptosis-Related Genes in Cancer 
3.1. Extrinsic Pathway  
3.1.1. Death Receptor 
Aberrant methylation in the promoters of gene coding for proteins implicated in the extrinsic 
pathway could be responsible of early blocking events in apoptosis. A decrease in Fas expression has 
been observed in p53 mutated cancer cells. Two distinct regions controlling Fas expression are 
sensitive to methylation. The Fas promoter contain a 650 pb CGI (28 CpG sites) in the 5’flanking 
region and a second CGI in intron 1. Such aberrant methylation has been reported in Fas promoter in 
T-cell lymphoma or in colon carcinoma cell lines and also correlated to a decrease in Fas expression, 
thus conferring apoptosis resistance independently of the p53 status. Conflicting results have been 
reported on the correlation between methylation and Fas gene silencing. Butler et al. [101] proposed 
that in colorectal carcinomas Fas silencing might not be due to promoter methylation as they did not 
find any methylation in the 9 CpG located in the Fas promoter. However, it should be noted that this 
study did not include a large area of the promoter, such as the CpG site at -548 position, the only CpG 
methylated in RKO cells, the demethylation of which by 5-azadeocytidine restored Fas expression and 
apoptosis. Specific methylation of p53 binding site in intron 1 may also explain the efficient Fas 
silencing in some colon cancers [64]. Aberrant methylation in the promoters of DcR1, DcR2, DR4 and 
DR5 have been reported in neuroblastoma tissue or cell lines and inversely correlated to expression of 
these genes. TNFRSF10c belongs to the tumor necrosis factor receptor family and has also been 
frequently deleted in many cancers but silencing of the TNFRSF10C gene in pancreatic cancers occur 
predominantly by hypermethylation in CpG islands associated with apoptosis resistance [95]. 
3.1.2. Caspase 8 (Casp 8) 
Whereas, according to literature, methylation of Fas or DcR/DR genes are rare events, many reports 
have shown the frequent hypermethylation of the promoter of Casp 8 in many different cancers (Table 1). 
Methylation in the Casp 8 promoter generally correlated with a low Casp 8 expression, and low 
apoptosis sensitivity to trail and was reversed in different cancer cell lines as lung cancer cells, using a 
5-azadeoxycytidine treatment, an inhibitor of DNA methylation. While mechanisms governing genes 
hypermethylation in cancers—in particular in apoptosis pathways are until now poorly understood—
some initial results have been proposed to explain the hypermethylation of the Casp 8 promoter. Kurita  
et al. [102] reported that both invalidation of Dnmt1 and Dnmt3b was required to reverse Casp8 
promoter methylation and induce gene reexpression in human hepatoma cells. However, we recently 
reported that Casp8 methylation correlated with both Dnmt1 and Dnmt3a, but not with Dnmt3b [34]. 
These reports strongly support a role for cooperation between Dnmt1 and dn  Dnmts in Casp8 
methylation. The requirement of Dnmt3a or Dnmt3b might be governed by tissue or CpG specificity. 
Dnmt1/Dnmt3b cooperation has already been described for methylation of survival genes (p16, 
BAGE1, CXCL12). Molecular mechanisms at the origin of Casp8 methylation have been partially 
analyzed. The methylation in the SP1 box located at -97 position completely abolished SP1 complex 
recruitment and Casp 8 expression [103]. Similarly, in neuroblastoma, 63% of tumors presenting   Cells 2013, 2  551 
 
 
c-MYCN oncoprotein amplification were also associated with methylation of Casp 8 whereas only 6% 
of tumors without c-MYCN amplification were methylated [104]. With regards to the new roles of TFs 
(Transcription Factors)/Dnmts interaction in gene silencing, these observations might suggest a role for 
SP1 and/or c-MYCN in Casp8 methylation. Moreover, few regulators of the extrinsic pathway are 
known. Methylation-dependent silencing of these proteins could also play a role in apoptosis resistance 
in cancer cells. 
3.1.3. TMS1/ASC (target for methylation-induced silencing-1/apoptosis-associated speck-like protein 
containing CARD-ASC). 
A CGI gene called TMS1/ASC encodes for a pro-apoptotic tumor suppressor protein composed of 
PYD (pyrine domain) and CARD motifs. Activation of TMS1 is able to induce apoptosis in a Casp  
8-dependent manner (Figure 1). A high frequency of methylation was found in TMS1 promoter in 
many tumors and the density of methylation inversely correlated both, in tissue and cell lines, to TMS1 
expression as illustrated in glioma cells [105]. Invalidation of TMS1 in cultured cells induced a partial 
protection against TRAIL-induced p53-mediated apoptosis, however, contribution of TMS1 
methylation to cancer progression is not clear as no correlation could be found between methylation 
and pathological changes in several cancers including cholangiocarcinoma [88,106]. Since TMS1 
methylation in normal tissue adjacent to prostate tumors was significantly more frequent in patients 
with biochemical recurrence, the TMS1 methylation event was suggested to contribute to 
aggressiveness in some cancers. The latter observation was validated in neuroblastoma patients 
showing links between TMS1 methylation and shorter survival curves [85,107]. TMS1  mediated-
methylation was significantly higher in clear cell ovarian tumors than in other ovarian cancer types, 
suggesting different roles of TMS1 inactivation in tumors from different tissues but also from the same 
organ [90]. Interestingly, Das et al. [108] reported a significant difference in methylation frequencies 
in  TMS1 promoter in prostate cancers based on racial criteria (black or white) associated with a 
mortality ratio two-fold higher in the black male population. Environment, diet and ethnic habits are 
supposed to influence methylation status of genes and might contribute to epigenetic-mediated 
tumorigenesis. Silencing machinery controlling TMS1  methylation has been poorly studied. TMS1 
silencing could result from dense methylation in CGI combined with hypoacetylation in H3 and H4 
and the modification of the chromatin structure in CGI. In glioma patients, TMS1 methylation was 
correlated with Dnmt3b content and overexpression of Dnmt3b caused an increase in TMS1 
methylation, while Dnmt3a overexpression had no effect. In glioma cells, corecruitment of Dnmt1, 
Dnmt3b and HDAC1 on the TMS1 promoter suggest a silencing complex requiring a cooperation 
between DNA methylation and hypoacetylation [34]. While no association was found between Dnmt1 
and TMS1 expression, Dnmt1 is a member of the silencing complex; moreover, overexpression of 
Dnmt1 in fibroblast was also silenced in a DNA methylation manner the TMS1/ASC  gene [109]. 
Indeed, recruitment of MBD3 on the TMS1 promoter in prostate cancers also suggested a role for the 
the NuRD complex in TMS1 silencing. Cells 2013, 2  552 
 
 
3.2. Intrinsic Pathway  
3.2.1. Bax 
Methylation in the Bax promoter induced a strong decrease or complete silencing of Bax expression 
in glioma cells or glioma patients. Moreover, silencing of Bax by RNAi conferred a resistance to Fas 
ligand-mediated apoptosis in cell culture suggesting a role of methylation-mediated Bax silencing in 
apoptosis resistance in GBM. The low number of GBM patients presenting Bax silencing does not 
permit a serious statistical survival analysis [20,34]. However, it should be noted that in a cohort of 27 
GBM patients, the patient presenting a Bax inactivation via methylation had the lowest survival curve. 
Interestingly, our group reported another distinct methylation profile of Bax, which was called BaxΨ 
and this methylation profile correlated with an extended survival curve in glioma patients [20]. BaxΨ 
isoform was induced by methylation within intron 1 of the gene and induced the expression of a 
truncated form of Bax (Bax
p18), which was more apoptogenic than Bax
p21 (Figure 2C). Both intron 1 
and exon 1 methylations were observed in non expressing Bax cells, suggesting that BaxΨ profile 
might be an intermediary step in Bax silencing. 
3.2.2. Bcl2 
Surprisingly, a frequent hypermethylation of two CpG in the Bcl2 promoter was observed in 
prostate cancer and was associated with a decrease in Bcl2 expression [110]. The implication of Bcl2 
methylation in prostatic cancer is not understood and has to be balanced by the additional decrease 
expression of pro-apoptotic protein such as Bak and Bik in these cancers. In glioma patients, Bcl2 
methylation correlated both with global DNA methylation as well as another methylation of the anti-
apoptotic gene BclXL, suggesting common methylation mechanisms and this was associated with an 
increase in intra tumor apoptosis [34].  
3.2.3. BH3-only 
BH3-only genes encode for pro-apoptotic proteins capable of sequestering anti-apoptotic proteins 
such as Bcl2 or BclXL (Figure 1). Several BH3-only genes are methylated in cancers. A decrease in 
HRK (Harakiri) expression was found in different cancers including prostate or glioma cancers and 
was associated with apoptosis resistance. HRK gene inactivation frequently resulted from a 
combination of an initial loss of one allele and a further methylation of the second allele [111]. 
Surprisingly, HRK methylation was significantly higher in gastric tumor or glioma patients presenting 
WT p53 suggesting a role of this protein in the specific methylation of this gene. Literature suggests 
that HRK methylation is not always correlated to a decrease in HRK expression. Indeed, some large 
regions, which are very frequently methylated, seem to be those which are the least associated with 
silencing, while a dense methylation of few CpG closed to transcriptional initiation site abrogated HRK 
expression [66]. Finally, deacetylation of H3 and H4 also regulate HRK silencing. Specific methylation 
of  Puma gene have been reported and associated to gene silencing in lymphoma while BIM was 
methylated in CML [11,32,33]. BIK inactivation in a mutational manner is observed in lymphomas, 
but epigenetic modification seems to be also implicated in BIK silencing in other cancers as Multiple Cells 2013, 2  553 
 
 
Myeloma [27]. BIK is methylated in glioma and in several cell lines but studies on a direct link 
between methylation and low expression is still under discussion. Nevertheless, inhibitors of DNA 
methylation in RCC cell lines induces a strong increase in BIK expression and abrogated apoptosis 
resistance. A synergic increase in both mRNA and BIK protein in HCC cells was observed following 
treatment with both inhibitors of Dnmt and HDAC suggesting a cooperation between deacetylation and 
DNA methylation occurs in BIK silencing [24,112]. 
3.2.4. BCL2L10 
BCL2L10 belongs to the Bcl2 family but some conflicting results described this protein as pro or 
antiapoptotic. Yet, Xu et al. [21] reported that three sites where hypermethylated and three additional 
sites were partially methylated in BCL2L10 promoter in gastric tumor tissue and correlated with a 
decrease in the corresponding protein. Moreover, silencing of the gene was correlated to an increasing 
tumor size in these patients. 
3.2.5. APAF-1 (Apoptotic Protease-Activating Factor 1) 
APAF-1 silencing is frequently observed in melanomas and is partly due to LOH. As 5-aza 
treatment dramatically increased APAF-1 expression in methylated melanoma or leukemia cells but 
not in bladder cells, the link between APAF-1 methylation and gene silencing is not clear and might be 
tissue-dependent [18]. APAF-1 methylation correlated with tumor grade in bladder cancers, RCC or 
neuroblastoma, but while a significant increase of APAF-1 methylation was also observed in testicular 
germ cells tumors, the relative abundant basal APAF-1 methylation in non tumoral tissue leads to a 
difficult interpretation of its role in tumorigenesis [16,85,113]. Since no correlation between APAF-1 
mRNA and APAF-1 protein content could be found, post-translational modification of APAF-1 are 
suspected to be dramatically involved in apoptosis sensitivity [114]. However, inhbition of APAF-1 
methylation by 5-aza deoxycytidine, restores the Apoptosome formation and the activation of Casp 9. 
On one hand, specific methylation of CpG were found in a region from +87 to +128 in leukemia and 
not in normal cells, and on the other hand, no modification in the methylation rate in CGI (−680 +420) 
of the gene could be found between melanomas and normal cells, leading to the idea that methylation 
of an enhancer, still unknown until now, could also be implicated in the phenomenon [17]. Finally, an 
increase in Dnmt1 content is suspected to favor APAF-1  methylation whose complete silencing 
probably requires the recruitment of the additional corepressors HDAC1 and MBD2. 
3.2.6. Inhibitor Apoptis Proteins (IAPs) 
Inhibitor Apoptosis Protein (IAP) is composed of eight members presenting from one to three BIR 
domain from the baculovirus. IAPs antagonized effectors caspases : Casp 3, Casp 7 and Casp 9, and 
inhibit apoptosis. A loss of methylation in these promoters might be related to apoptosis resistance. 
Five IAP promoters (ciAP1, ciAP2, Survivin, NAIP and XIAP) were hypomethylated in oral tumors 
and a strong correlation of expression between each other suggests some common regulatory 
mechanisms. However, any correlation between IAP expression and malignant transformation in oral 
tumors was found, suggesting that a gain in expression of IAP genes might only partially contribute to Cells 2013, 2  554 
 
 
tumorigenesis and not be at its origin [115]. Survivin is normally expressed during embryogenesis and 
shut down in adult differentiated tissues. Strikingly, Survivin hypomethylation and high 
overexpression of the protein has been found in different cancers including ovarian, HCC(Hepato 
Cellular Carcinoma) and glioma. A correlation between Dnmt1 level and Survivin methylation status 
suggest that Dnmt1 is required for Survivin regulation. Esteve et al. [116] proposed that Survivin 
silencing was mediated by a heterotrimer SP1/Dnmt1/p53 complex initiated by TFs/Dnmts interactions 
and specific recruitment of Dnmt1 on TF-Boxes. 
3.2.7. BNIP3 
The TSG, BNIP3 (Bcl2/adenovirus E1B 19KDa interacting protein 3) is normally activated by HIF 
(hypoxia inducible factor) in response to hypoxia and can promote apoptosis. As chronic hypoxia is a 
hallmark of environment of many solids tumors, cancers have frequently developed strategies of 
resistance, and among them, the monoallelic deletion of BNIP3. Indeed, CpG islands were found from 
the 5' end to the intron 2 (−1162/+538) of BNIP3 gene and methylation in these sites correlated with 
low expression of BNIP3 in pancreatic tumors where most of the CpG analyzed were specifically 
methylated in tumoral tissue [117]. Silencing of the gene could be explained by the presence of 4 SP1 
motifs in the methylated region and methylation in the vicinity of HRE binding site in pancreatic 
tumors. Relationships between inactivation of BNIP3 gene and survival is confusing. However, forced 
expression of BNIP3 in pancreatic tumoral cell lines leads to apoptosis. Survival time of patients with 
BNIP3 methylation was shorter than in absence of methylation in gastric tumors, whereas no such 
association could be found in breast tumors [28]. In addition, patients with methylation exhibited resistance 
to chemotherapy compared to patients with no methylation, suggesting that methylation of BNIP3 is a 
predictive factor in the prognosis and response to treatment in colorectal cancer patients [118–120]. 
3.2.8. XAF-1 
The pro-apoptotic protein XAF-1 (XIAP-associated Factor 1) is the main inhibitor of XIAP by 
inducing its sequestration (Figure 1). No canonical CGI could be found in promoter but two shorts 
regions (I and II) quite rich in CpG were found within -1867/-343 area but methylation in both I and II 
appeared not critical for XAF-1 expression in gastric cancers [99]. These authors demonstrated that 
XAF-1 expression was rather tightly controlled by the methylation status of seven independent CpG 
localized in the proximity of the transcriptional initial start site (-234/-23). Common and additional 
methylated sites in -164 to 109 were found in colon carcinoma cell lines suggesting tissue-specific 
mechanisms of inhibition particularly the two CpG located to the transcriptional start site [121]. 
Indeed, similar results from Lee et al. reported that XAF-1 hypermethylation of total or partial 14 CpG 
loci from -20 to -695 of the promoter, was associated to a decrease in XAF-1 expression and is 
correlated with disease progression, in particular malignancy in bladder cancers [122]. 
3.2.9. Death Associate Protein Kinase (DAPK) 
Death associated protein kinase (DAPK) gene encodes for a Ca+/calmodulin-regulated Ser/Thr 
kinase including a death domain and is involved in both intrinsic and extrinsic apoptosis. DAPK Cells 2013, 2  555 
 
 
promoter is the most frequently apoptosis-related gene aberrantly methylated in cancers at frequencies 
often from 70–90%. Methylation of DAPK promoter is clearly associated to disease in many cancers. 
As some examples, patients with DAPK methylation in gastric cancers present a response rate 
significantly lower than patients without methylation and DAPK methylation also correlated with 
grade in testicular tumors, recurrence in bladder tumors, or invasion and metastasis in lung   
cancers [93,98,123]. Conversely, any influence of DAPK methylation could be found on prognosis in 
malignant mesothelioma as neither CXCA patients and overexpression of DAPK increased the 
radiosensitivity of SiHa cells [42,46]. As methylation correlated to low DAPK expression,   
Mittag et al. [51] suggested that methylation of DAPK conferring apoptosis resistance was an early 
event in tumorigenesis and several molecular explanations have been proposed. DAPK gene present a 
CGI extending 2500 pb from the transcriptional start site. A high heterogeneity of methylation of CpG 
was found in lung cancers suggesting that some CpG are more particularly associated with gene 
silencing than others. Methylation in the intron 1 partially correlated to DAPK expression while those 
included in 5’flanking region are more related to DAPK silencing [53]. In cancer cells, edge of CGI is 
more sensible to methylation than the center but is not associated to gene expression regulation [124]. 
It has been hypothesized that initial methylation of edge of CGI, particularly in a repetitive element, 
such as Alu sequences, could bring a functional anchorage of methylation machinery for further 
methylation toward the center of the CGI which would affect gene expression. Indeed, a frequent 
methylation in the exon 2 of cancer cells was not correlated to low expression. Pulling et al. [125] also 
recently revealed two methylation hot spots containing each 8-10 CpG whose methylation abolished 
DAPK expression. Methylation occurring in the vicinity of CP2 or FOXA2 binding sites negatively 
controlled the expression of the two promoters of DAPK. Concomitantly to DNA methylation, 
deacetylation of histones H3 and H4 was observed suggesting a complex including Dnmt and HDAC 
in DAPK silencing [124]. A role of DAXX on DNA hypermethylation has recently emerged. DAXX is 
a dual protein: i) implicated in apoptosis and ii) is a transcriptional regulator able to bind to HDAC and 
Dnmt to repress gene transcription. DAXX can not directly bind to DNA and Puto et al. [126] 
demonstrate that its repression activity was mediated via RelB interaction (Figure 2B). Formation of 
the ternary DAXX/Dnmt1/RelB complex transformed the transcriptional activity of RelB into a 
repressor complex by inducing a targeted methylation-mediated silencing on RelB-binding sequences 
in several genes including DAPK. Participation of chromatin remodeling enzymes was confirmed by 
the co-recuitment of HDAC2 on DAXX. 
3.2.10. Ras Association Doman Family 1A (RASSF1A) 
Ras association domain family 1A (K-Ras/ RASSF1A) complex can activate Bax via an additional 
intermediately interaction with MOAP-1. In spite of absence of TATA box (also called Goldberg-Hogness 
box), methylation in CGI adjacent to the transcription initiation site induced gene silencing and 
RASSF1A methylation was considered has a good prognosis marker in breast, CRCC and some lungs 
cancers [127]. Some results in other cancers are less convincing, such as the absence of a correlation 
between methylation and clinical parameters or the observation that while RASS1FA is methylated at 
48–60% in bladder cancers, a strong methylation (42%) was also found in normal corresponding 
tissue [128,129]. Interestingly, recent reports brought uncommon molecular mechanisms in RASSF1A Cells 2013, 2  556 
 
 
methylation. Tian et al. [77] demonstrated that p53 was recruited on the p53 binding site located in 
distal promoter specifically in testis tumors but not in normal tissue and correlaled to DNA 
methylation in the proximal promoter (Figure 2A). A first recruitment of the HDAC1/SETDB1 (a 
histone methyltransferase) complex was supposed to initiate epigenetic marks on RASSF1A promoter. 
Secondly, RASSF1A methylation was achieved by the following recruitment of Dnmt3a favored by 
direct binding with both HDAC1 and SETBD1 [130]. Moreover, the ΔDnmt3b4 isoform of Dnmt3b 
lacking exon 6, appeared essential for RASSF1A silencing in a methylation manner in lung cancer, 
demonstrating for the first time the role of Dnmt isoforms in dn methylation in cancer cells [131]. 
Figure 2. Mechanisms of DNA hypermethylation and apoptosis-related genes inactivation 
(a) Inactivation of RASSF1A by Dnmt/P53 cooperation. (b) Inactivation of DAPK by the 
ternary complex Dnmt/RelB/DAXX. (c) Specific methylation of BAX leading to BAX ψ or 
BAX silencing. 
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3.2.11. Secreted Apoptos-Related Protein 2 (SARP2)  
Secreted Apoptosis-Related Protein (SARP) families are considered to counteract the oncogenic 
Wnt signaling pathway, and inactivation of this gene may aid cancer development and progression. Cells 2013, 2  557 
 
 
SARP proteins, also named sFRP (for Secreted Frizzled-Related Protein), exert differential effects on 
osteoblastic differentiation of mouse mesenchymal cells and cellular apoptosis of mouse osteoblasts in 
vitro [132]. SARP2 methylation has been reported in several cancers such as pancreatic tumors with 
very high frequencies. SARP2 methylation may occur in the steps of pancreatic tumorigenesis as 
SARP2 methylation was observed in both begnin and malignant tumors and no statistical link could be 
found between SARP2 methylation and disease progression [84].  
3.2.12. Interferon Regulatory Factor 8 (IRF8) 
Interferon regulatory factor 8 (IRF8) is an apoptosis-regulating gene that has been demonstrated to 
directly regulate Bax transcription in vivo [133]. IRF8 is hypermethylated in different types of cancer 
and is an essential regulator in Fas-mediated apoptosis pathway. Moreover, IRF8 is a metastasis 
suppressor in solid tumors and metastatic tumor cells use DNA hypermethylation to repress IRF8 
expression to evade apoptotic cell death and to acquire a metastatic phenotype in human colon 
carcinoma [134]. IRF8 was also identified as a functional tumor suppressor, which is frequently 
silenced by epigenetic mechanism in multiple carcinomas [135]. Finally, silencing of IRF8 expression, 
by DNA methylation or other epigenetic mechanisms, may be associated with the malignant phenotype 
of Multiple Myeloma [136]. 
4. Significance of Methylation in Cancers 
As seen above, mechanisms governing de novo methylation in apoptosis related genes are poorly 
understood and often completely unknown. A significant decrease in Dnmt3a content has been 
recently reported during TRAIL-induced apoptosis in rat hepatic cells [137]. It was generally believed 
that promoters with low CpG content were easily methylated but that they did not severely affect gene 
transcription. Similar hypotheses were proposed for a low percentage of methylation in high CpG 
regions. Nevertheless, in regards to increasing knowledge of DNA methylation mechanisms, reality 
may be much more complicated. Methylation of one site in 300pb in several promoters could be 
efficient to repress transcription. In some cases, specificity of Dnmt has been proposed, as the 
requirement of Dnmt3b or Dnmt1 for promoter methylation of TMS1 or Survivin, respectively. Some 
recent works converging from several laboratories have demonstrated the existence of targeted 
methylation via Dnmts/TF interactions. The TF PU.1 physically interacts with Dnmt3a and mediated 
gene silencing via PU.1-binding sites in the promoters [55]. Similar observations with Dnmts/TF 
interactions have been described for p53 and cMyc [138,139]. 5-aza-deoxycitidine activates p53 
signaling pathway and apoptosis cells [140]. As p53 is (i) a key regulator of apoptosis and (ii) control 
the transcription of many apoptosis related-genes, silencing via methylation of p53 binding sites by the 
Dnmt3a/p53 complex may confer a signature participating in apoptosis resistance. We demonstrated 
that TF-mediated targeted methylation could be a frequent phenomenon as Dnmt1, 3a and 3b 
potentially interacts with a large panel of TFs in vitro [141,142]. Methylation of SP1-binding sites has 
been reported in silencing of beclin. We recently validated Dnmt1/SP1 or Dnmt3/SP1 interactions. 
Modulation of theses complexes in tumoral cells could contribute to de novo methylation in apoptosis 
related genes promoters. Moreover, different Dnmt1/TFs complexes are observed in the different 
phases of a cell cycle, which means that targeted DNA methylation may be dependent on the Cells 2013, 2  558 
 
 
accessibility of each TF [143]. EZH2 has been implicated in DAPK silencing. An increase of EZH2 
expression in prostate and glioma cancers compared to normal tissue and a strong correlation between 
EZH2 level and bladder cancer stages may suggest that Polycomb group could partially control gene 
silencing observed in these tumors [15,70,144]. An illustration of this mechanism was the EZH2-
mediated silencing of hDAB2IP, a GTPase-activating protein modulating apoptosis in prostate tumors. 
As APAF-1 expression is regulated by E2F1, SP1 and p53, further studies on possible mechanisms of 
targeted methylation and stabilization and kinetics of Dnmt/E2F1, Dnmt/SP1 or/and Dnmt/SP1 
complexes may lead to understand the APAF-1 silencing in tumors. 
We have seen above that numerous genes implicated in apoptosis could be aberrantly methylated in 
cancers and this was often associated to apoptosis resistance. Netherveless, hypermethylation of pro-
apoptotic genes may not always associated with survival curve differences or grade. In CxCa (Cervical 
cancer), correlation of methylation have been found between Fas and DAPK in one hand and TRAILR1 
and Fas in another hand [63]. Authors suggested that high apoptosis resistance in tumor cells could 
resulted from the silencing of several apoptosis related genes issued from common or different 
mechanisms. Similarly, combined methylation of TMS1 and DAPK in gastric cancers was associated to 
patients with a shorter survival curve in comparison to patients with only one methylation or no 
methylation [47]. Our recent work agree with these observations [34]: among eight genes related to the 
apoptotic program, only methylation status of Bax correlated to survival curve. As all these genes are 
included in a global cascade, we proposed that in glioma patients, each methylation could contribute to 
a small part in apoptosis resistance. A value of +1 was attributed to each tumor harboring a 
methylation in a gene coding a pro-apoptotic protein and −1 was attributed to each tumor harboring an 
unmethylation of an anti-apoptotic gene. Glioma patients scores revealed a strong correlation between 
score and apoptosis level and moreover, patients with the lowest score presented a significantly shorter 
survival curve. Similar clusters of gene methylation demonstrated a shorter survival in mesothelioma 
patients with combined methylation of DAPK, RASSAF1A and RARβ while no association was found 
for each methylation independently. Moreover, clustering of patients with three hypermethylated genes 
compared to unmethylated genes or one hypermethylated gene severly decrease the survival in 
neublastoma patients [85]. 
Recently, microRNAs (miRNAs) have been implicated in regulation of gene expression and of 
apoptosis-related gene expression. MiRNAs are small noncoding RNAs that function as endogenous 
post-transcriptional silencers of target genes. MiRNAs are expressed in a tissue specific manner and 
play important roles in cell proliferation, apoptosis and differentiation. Some miRNAs promoters are 
controlled by epigenetic alterations such as DNA methylation [145]. Anti-apoptotic genes BCL2L2 and 
E2F6 are targets of miR-205 and miR-31, respectively. By downregulating Bcl-w and E2F6, miR-205 
and miR-31 promote chemotherapeutic agents-induced apoptosis in prostate cancer cells. The 
promoter region of the miR-205 gene was found to be hypermethylated in cell lines derived from 
advanced prostate cancers, contributing to the downregulation of the gene [146]. Moreover, miR-214 
promoter is regulated by DNA methylation and reduces cell survival, induces apoptosis and enhances 
sensitivity to cisplatin through directly inhibiting Bcl2l2 expression in cervical cancer cells [147]. In 
many tumor types the promoters of the miR-34a and the miR-34b/c genes are subject to inactivation by 
CpG methylation. MiR-34a is commonly deleted in neuroblastomas. Furthermore, the loss of miR-34 Cells 2013, 2  559 
 
 
expression has been linked to resistance against apoptosis induced by p53 activating agents used in 
chemotherapy [148].  
5. Therapeutical Strategies 
As seen above, methylation of several genes are associated with disease progression, survival, 
tumoral grade or metastasis and detection of these aberrant methylation in apoptosis genes could be 
used as markers of disease and constitute potential markers of prognosis in patients. Detection of such 
aberrant DNA methylation could be made in serum patients as illustrated in gastric cancers or in urine 
for bladder cancer patients [15,47,55,63,70,77,84,128–149]. Systematic research of methylation 
markers of disease in serum or urine might constitute a new non invasive approach for efficient 
detection and prognosis of cancer in the future. 
Chemical agents targeting methylation machinery demonstrated positive effects against apoptosis 
resistance in both in vitro and in vivo studies. These interesting results lead to their proposal for 
clinical studies in cancer treatments. Natural compounds like green tea polyphenols such as EGCG 
have the potential to affect multiple biological pathways, including gene expression, growth   
factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, and the 
ubiquitin/proteasome degradation pathway [150]. The effects of dietary polyphenols such as EGCG on 
DNMTs appear to have their direct inhibition by interaction with the catalytic site of the DNMT1 
molecule, and may also influence methylation status indirectly through metabolic effects associated 
with energy metabolism [151]. These bioactive components are able to modulate epigenetic events, and 
their epigenetic targets are known to be associated with breast cancer prevention and therapy [152,153]. 
Therapeutic activity of hypomethylating agents such as decitabine (DAC, Dacogen™; MGI Pharma, 
Inc.) and 5-azacytidine (AZA, Vidaza™; Celgene Corp.) have been used in clinical approaches in 
patients with myelodisplasic syndromes (MDS). Phase III clinical trials gave 60% of response in the 
arm treated with 5-aza and among them 7% of patients obtained a complete remission. Survival was 
increased from 14 months to 20 months. Similar studies were realized with decitabine, which gave a 
17% response in a large phase III study. Global DNA hypomethylation induced by 5-azacytidine is 
progressive and related to cell cycle status [154]. Cells with large hypomethylation underwent 
apoptosis while cells without DNA hypomethylation were still alive. Several in vitro studies in 
different cancer cell lines demonstrated an efficient demethylation-dependent increase of pro-apoptotic 
proteins like DAPK and Bcl2L10 [22]. In vitro and in vivo studies in rodents demonstrated positive 
effects on combined decitabine and TRAIL death inducer on apoptosis sensibility of glioma cell lines 
mediated by both TRAILR1 and caspase-8 reexpression in a demethylation manner [155]. Moreover, a 
large portion of tumor-infiltrating CD8(+) T cells are FasL(+), and a critical role for FasL in decitabine 
and vorinostat-mediated tumor suppression in vivo is suggested. These data imply that combined 
modalities of chemotherapy to sensitize the tumor cell to Fas-mediated apoptosis and CTL 
immunotherapy is an effective approach for the suppression of colon cancer metastasis [156]. On the 
other hand, global DNA methylation and local hypomethylation in oncogenes or genes favoring 
apoptosis resistance argue in the addition of lipotropes (methionine, choline, folate, VitB12) as methyl 
donors to both prevent and limit aggressiveness. Treatment of glioma cells with folate reduced global 
hypomethylation, proliferation index and increased apoptosis sensitivity [157]. Similar results were Cells 2013, 2  560 
 
 
observed in breast cancer cell lines [158]. Moreover, a delay in occurrence and a decrease in tumor 
size was observed in glioma chemo-induced rats treated with folate compared to normal diet [159]. 
Several mechanisms could explain these results. Invalidation of Dnmt1 has been associated to global 
DNA methylation, chromosal instability and lymphomas [160]. As a partial cooperation between de 
novo and maintaining Dnmts have also been reported increasing methyl donors accessibility may 
palliate mMase defects in cancers mainly promoted by Dnmt1/PCNA/URHF1 disruption and limit 
further chromosomal instability and local hypomethylations. Increasing dnMase activity is also 
supported by an increase in both Dnmt3a and 3b genes expression in glioma cells treated with folate in 
response to detachment of SP1 in favor of SP3 in these promoters.  
6. Conclusions  
Recent findings on targeted DNA methylation open new perspectives for therapeutical studies. 
Implication of c-Myc, p53 and SP1 in aberrant methylation of gene coding for pro-apoptotic proteins 
has to be more investigated. Systematic analysis of potential TF/Dnmt interaction revealed by in vitro 
studies may also reveal new specific interactions implicated in apoptosis resistance in cancer cells. By 
blocking these interactions, we could imagine both restore a specific demethylation of selective genes 
in cancer cells and apoptosis sensibility. This strategy would conturn significant side-effects currently 
produced by unspecific drugs like demethyl agents. While 5-aza treatment reduced apoptosis resistance 
in several cancer cell lines, prolonged exposition is associated with global DNA hypomethylation and 
activation of invasiveness pathway genes like UVA both in vitro and in vivo [161]. Combinations of 
existing therapies towards proliferative cells and specific reactivation of apoptosis sensitivity would 
constitue new therapies being more adapted to each patient in the future (Figure 3). 
Figure 3. DNA methylation and anti-apoptotic strategies (a) Effects of both DNA 
demethylating agents and pro-methylation, mediated by folate, on apoptosis-related genes 
and apoptosis. (b) Conflicting results of demethylated agents and specific strategies against 
targeted DNA methylation on apoptosis.  
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